At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
GT103drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
In Brief
A Phase 1 clinical trial evaluating GT103 for Non-small Cell Lung Cancer. Completed, enrolled 31 participants across 3 sites.
Detailed Summary
The purpose of this research study is to determine the maximum tolerated dose of GT103 and investigate the safety and effectiveness of the study drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartJun 2020
Primary CompletionApr 2024
Study CompletionDec 2024
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartJun 9, 2020
Primary CompletionApr 11, 2024
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.3 years ago
Interventions
GT103drug
intravenously (dose depending)